185 related articles for article (PubMed ID: 16865646)
21. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
22. [Medullary thyroid carcinoma: the comparison of the hereditary and sporadic types of cancer].
Wygoda Z; Oczko-Wojciechowska M; Gubała E; Pawlaczek A; Kula D; Wiench M; Włoch J
Endokrynol Pol; 2006; 57(4):407-14. PubMed ID: 17006845
[TBL] [Abstract][Full Text] [Related]
23. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
24. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
Chang CF; Yang WS; Su YN; Wu IL; Chang TC
J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
[TBL] [Abstract][Full Text] [Related]
25. Genetic testing in multiple endocrine neoplasia and related syndromes.
Calender A
Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
[TBL] [Abstract][Full Text] [Related]
26. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
[TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
28. Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma.
Yeganeh MZ; Sheikholeslami S; Dehbashi Behbahani G; Farashi S; Hedayati M
Tumour Biol; 2015 Jul; 36(7):5225-31. PubMed ID: 25694125
[TBL] [Abstract][Full Text] [Related]
29. [Genetic analysis of RET mutations in families with multiple endocrine neoplasia type II in the community of Murcia].
Pomares Gómez FJ; Bernabé Espinosa MJ; Matías-Guiu Guía X; Rodríguez González JM; Soriano Palao J; Sola Pérez J; Carbonell Meseguer P; Parrilla Paricio P; Tébar Massó FJ
Med Clin (Barc); 1999 May; 112(17):646-50. PubMed ID: 10374185
[TBL] [Abstract][Full Text] [Related]
30. Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.
Milićević S; Bergant D; Žagar T; Perić B
Croat Med J; 2021 Apr; 62(2):110-119. PubMed ID: 33938650
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
[TBL] [Abstract][Full Text] [Related]
32. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.
Marsh DJ; Robinson BG; Andrew S; Richardson AL; Pojer R; Schnitzler M; Mulligan LM; Hyland VJ
Genomics; 1994 Sep; 23(2):477-9. PubMed ID: 7835899
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
34. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
35. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
36. Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A; Lorenz K; Weber F; Dralle H
Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
[TBL] [Abstract][Full Text] [Related]
37. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance.
Heshmati HM; Gharib H; Khosla S; Abu-Lebdeh HS; Lindor NM; Thibodeau SN
Mayo Clin Proc; 1997 May; 72(5):430-6. PubMed ID: 9146685
[TBL] [Abstract][Full Text] [Related]
38. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
[TBL] [Abstract][Full Text] [Related]
39. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
